Should Apixaban (Eliquis) Be Held After a Fall?
Do not routinely hold apixaban after a fall in patients with atrial fibrillation or other strong indications for anticoagulation—the thrombotic risk from discontinuation far exceeds the bleeding risk from continuation, even in patients with recurrent falls. 1, 2
Key Evidence on Falls and Anticoagulation Risk
Patients would need to fall over 458 times per year for apixaban's risk to outweigh its stroke prevention benefit compared to aspirin alone, making fall risk an invalid reason to withhold anticoagulation. 2
In the ARISTOTLE trial, patients with a history of falling on apixaban had similar rates of stroke/systemic embolism and hemorrhagic stroke compared to those without fall history, and apixaban remained superior to warfarin regardless of fall history. 1
Among patients with fall history in ARISTOTLE, subdural bleeding occurred in 5 of 367 warfarin-treated patients but 0 of 386 apixaban-treated patients, demonstrating apixaban's superior safety profile even in this high-risk population. 1
Prospective cohort data show that patients on oral anticoagulation at high risk of falls do not have significantly increased major bleeding risk (HR 1.09; 95% CI 0.54-2.21), and only 0.6 per 100 patient-years of major bleeds occurred directly after a fall. 3
When to Consider Temporary Interruption
Hold apixaban only if there is active pathological hemorrhage or specific high-risk trauma requiring urgent intervention. 4
Specific Clinical Scenarios Requiring Interruption:
Intracranial hemorrhage with mass effect or neurological deterioration: Hold apixaban and consider reversal with andexanet alfa (FDA-approved specific reversal agent). 5, 4
Major trauma with ongoing bleeding (e.g., hemodynamic instability, expanding hematoma, falling hemoglobin): Temporarily discontinue until hemostasis is achieved. 6, 4
Traumatic spinal/epidural puncture: Delay apixaban for 48 hours after traumatic neuraxial procedure. 4
Timing of Resumption After Interruption
Resume apixaban 48–72 hours after trauma once adequate hemostasis is confirmed (stable hemoglobin, no expanding hematoma, controlled pain). 6
Resumption Algorithm:
Within 24 hours: Avoid restarting—markedly increases major bleeding risk comparable to therapeutic LMWH. 6
24–48 hours: Consider resumption only in extremely high thrombotic risk patients (mechanical valve, recent stroke within 2 weeks, CHA₂DS₂-VASc ≥4) with documented hemostasis. 6
48–72 hours: Standard resumption window for most patients once bleeding risk is controlled. 6
Beyond 72 hours: Delaying further increases stroke/systemic embolism risk without meaningful bleeding reduction once hemostasis is established. 6
Dose Considerations on Resumption:
Restart at the patient's pre-injury dose (5 mg twice daily or 2.5 mg twice daily if dose-reduction criteria are met) once hemostasis is adequate. 6
For extremely high thrombotic risk patients, consider reduced initial dose of 2.5 mg twice daily for 2–3 days, then increase to full therapeutic dose to balance early re-bleeding protection. 6
Do not use heparin bridging during the 48–72 hour interruption—apixaban's rapid onset (peak 1–3 hours) and short half-life (7–8 hours) make bridging unnecessary and potentially harmful. 6
Critical Pitfalls to Avoid
Common Prescribing Errors:
Underdosing apixaban (giving 2.5 mg twice daily when 5 mg twice daily is indicated) occurs in 9.4–40.4% of prescriptions—this is the most common error and increases thrombotic risk. 6
Verify creatinine clearance (Cockcroft-Gault) before resuming, especially in patients with CrCl 30–50 mL/min who may require dose adjustment. 6
FDA Black Box Warning:
Premature discontinuation of apixaban without adequate alternative anticoagulation increases thrombotic event risk, with increased stroke rates observed during transitions in atrial fibrillation trials. 4
If discontinuing for reasons other than pathological bleeding, provide coverage with another anticoagulant to bridge the gap. 4
Monitoring After Fall
Monitor patients for at least 48 hours after apixaban resumption with daily hemoglobin assessment to detect occult bleeding and clinical surveillance for new thrombotic events. 6
Specific Monitoring Parameters:
Daily hemoglobin for first 48 hours post-resumption. 6
Neurological examination if head trauma occurred, even if initial imaging was negative. 1
Renal function assessment in elderly patients or those on nephrotoxic medications, as apixaban has 25% renal clearance. 6
Special Populations
Elderly Patients:
Female sex is associated with subtherapeutic apixaban concentrations, while standard dosing (10 mg/day) is associated with supratherapeutic levels in elderly patients. 7
In high-risk elderly patients (median age 79 years), therapeutic drug monitoring with dose adjustment based on apixaban plasma concentrations reduces bleeding events from 28% to 15% when concentrations are maintained within therapeutic range. 7
Patients with High CHA₂DS₂-VASc Scores:
Patients with atrial fibrillation, prior stroke/TIA, or heart failure are at high thrombotic risk and benefit from earlier anticoagulation resumption once hemostasis is confirmed. 6
The median CHA₂DS₂-VASc score in dialysis patients with AF is 4, indicating very high stroke risk that typically outweighs bleeding concerns. 8
Comparison with Other Anticoagulants
Apixaban's 25% renal clearance makes it safer than dabigatran (80% renal) in elderly patients with impaired renal function, allowing shorter interruption periods. 6
Apixaban demonstrates superior safety compared to warfarin in fall-prone patients, with no subdural bleeds versus 1.4% with warfarin in the ARISTOTLE fall cohort. 1